Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251 AM2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01189890
First received: August 25, 2010
Last updated: May 12, 2014
Last verified: May 2014
Results First Received: May 8, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: sitagliptin phosphate
Drug: Glimepiride
Drug: Placebo to Sitagliptin
Drug: Placebo to Glimepiride

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sitagliptin Sitagliptin phosphate 100 mg once daily (QD) or 50 mg QD
Glimepiride Glimepiride 1-6 mg QD

Participant Flow:   Overall Study
    Sitagliptin     Glimepiride  
STARTED     241     239 [1]
COMPLETED     204     200  
NOT COMPLETED     37     39  
Adverse Event                 3                 4  
Lack of Efficacy                 7                 2  
Lost to Follow-up                 1                 7  
Protocol Violation                 1                 5  
Withdrawal by Subject                 15                 11  
Non Compliance                 0                 1  
Physician Decision                 5                 4  
Hyperglycemia Discontinuation Criteria                 5                 5  
[1] 3 randomized glimepiride participants did not receive study drug.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sitagliptin Sitagliptin phosphate 100 mg once daily (QD) or 50 mg QD
Glimepiride Glimepiride 1-6 mg QD
Total Total of all reporting groups

Baseline Measures
    Sitagliptin     Glimepiride     Total  
Number of Participants  
[units: participants]
  241     239     480  
Age  
[units: years]
Mean ± Standard Deviation
  70.7  ± 4.8     70.8  ± 4.9     70.7  ± 4.8  
Gender  
[units: participants]
     
Female     130     148     278  
Male     111     91     202  
Hemoglobin A1c (HbA1c) [1]
[units: Percentage¬†of¬†HbA1c]
Mean ± Standard Deviation
  7.78  ± 0.70     7.78  ± 0.67     7.78  ± 0.69  
Fasting Plasma Glucose (FPG) [2]
[units: mg/dL]
Mean ± Standard Deviation
  168.4  ± 31.2     169.7  ± 35.5     169.0  ± 33.3  
Body Weight [3]
[units: kg]
Mean ± Standard Deviation
  76.9  ± 15.1     75.4  ± 16.4     76.0  ± 15.6  
[1] The population included all randomized participants who had a baseline HbA1c, did not take prohibited concomitant medications, had compliance >85%, and did not receive any incorrect study medication. Sitagliptin (n=197) and glimepiride (n=191).
[2] The population included all randomized participants who had a baseline FPG, did not take prohibited concomitant medications, had compliance >85%, and did not receive any incorrect study medication. Sitagliptin (n=194) and glimepiride (n=191).
[3] All randomized participants who received at least one dose of study treatment and had a body weight measurement at baseline. Sitagliptin (n=205) and glimepiride (n=203).



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30   [ Time Frame: Baseline and Week 30 ]

2.  Primary:   Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30   [ Time Frame: Up to Week 30 ]

3.  Primary:   Number of Participants Experiencing An Adverse Event (AE)   [ Time Frame: Up to Week 30 ]

4.  Primary:   Number of Participants Discontinuing Study Treatment Due to An AE   [ Time Frame: Up to Week 30 ]

5.  Secondary:   LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30   [ Time Frame: Baseline and Week 30 ]

6.  Secondary:   Percentage of Participants With HbA1c <7.0% at Week 30   [ Time Frame: Week 30 ]

7.  Secondary:   Percentage of Participants With HbA1c <6.5% at Week 30   [ Time Frame: Week 30 ]

8.  Secondary:   LS Mean Change From Baseline in Participant Body Weight at Week 30   [ Time Frame: Baseline and Week 30 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame Up to Week 32.
Additional Description The safety population consisted of all randomized participants who received at least one dose of study treatment.

Reporting Groups
  Description
Sitagliptin Sitagliptin phosphate 100 mg once daily (QD) or 50 mg QD
Glimepiride Glimepiride 1-6 mg QD

Serious Adverse Events
    Sitagliptin     Glimepiride  
Total, serious adverse events      
# participants affected / at risk     7/241 (2.90%)     6/236 (2.54%)  
Blood and lymphatic system disorders      
Anaemia † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Cardiac disorders      
Angina Unstable † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Atrial Fibrillation † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Cardiac Failure Chronic † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Gastrointestinal disorders      
Gastrointestinal Haemorrhage † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Inguinal Hernia † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Lower Gastrointestinal Haemorrhage † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Infections and infestations      
Gastroenteritis † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Colon Cancer † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Malignant Melanoma † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Prostate Cancer † 1    
# participants affected / at risk     1/241 (0.41%)     0/236 (0.00%)  
# events     1     0  
Nervous system disorders      
Nerve Compression † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Syncope † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Respiratory, thoracic and mediastinal disorders      
Pulmonary Embolism † 1    
# participants affected / at risk     0/241 (0.00%)     1/236 (0.42%)  
# events     0     1  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (15.1)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information